The Impact of a Prebiotics and Lactoferrin Containing Infant Formula on Stool Characteristics in Healthy Term Infants

NCT ID: NCT02363582

Last Updated: 2016-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

65 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-30

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Human milk (HM) is considered the gold standard nutrient for infants, which contains a lot of beneficial nutrients such as prebiotics and lactoferrin. Previous studies have shown that both prebiotics and lactoferrin play important roles in generating a bifidobacteria-dominated colonic microflora.The purpose of this study is to investigate the stool characteristics,acceptability, and gastrointestinal tolerance in term infants fed a starting infant formula supplemented with prebiotics and lactoferrin.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Human milk (HM) is considered the gold standard nutrient for infants, which contains a lot of beneficial nutrients such as prebiotics and lactoferrin. Previous studies have shown that both prebiotics and lactoferrin play important roles in generating a bifidobacteria-dominated colonic microflora as well as the intestinal immune systems. The purpose of this study is to investigate the stool characteristics(including intestinal microbiota) acceptability, and gastrointestinal tolerance in infants fed a starting infant formula supplemented with prebiotics and lactoferrin, and compared these data with infants on exclusively breast feeding.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infant Formula Intolerance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast fed

healthy term infants on exclusively breast feeding , enrollment age: 30-50days old

Group Type NO_INTERVENTION

No interventions assigned to this group

Formula fed

healthy term infants on exclusively formula fed , enrollment age: 30-50days old

Group Type EXPERIMENTAL

formula

Intervention Type OTHER

An infant formula contains prebiotics and lactoferrin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

formula

An infant formula contains prebiotics and lactoferrin

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* full-term with a birth weight ≥2,500 g
* be in good health
* without symptoms of diarrhea, and had not received antibiotics for at least 1 week before enrollment
* exclusively fed by breast milk or infant formula

Exclusion Criteria

* preterm infant
* with known diseases or currently taking medication drugs
* mixed feeding
* with symptoms of diarrhea
* received antibiotics within 1 week
Minimum Eligible Age

5 Weeks

Maximum Eligible Age

7 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jiang WU

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jiang Wu, MD

Role: PRINCIPAL_INVESTIGATOR

Xin Hua Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xin Hua Hospital

Shanghai, Shanghai Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SCMCIRB-K2013005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prebiotic in Preterm Infants
NCT03306316 COMPLETED NA
Breastfeeding Study
NCT03387124 COMPLETED